(19)

(11)

EP 4 680 196 A1

(12)

(43) Date of publication: 21.01.2026 Bulletin 2026/04 (21) Application number: 23748869.7 (22) Date of filing: 30.06.2023

(51) International Patent Classification (IPC):  A61K 9/00(2006.01) A61K 9/50(2006.01) A61K 35/00(2006.01) (52) Cooperative Patent Classification (CPC): A61K 9/5036; A61K 9/0024; A61K 35/39 (86) International application number: PCT/US2023/026739 (87) International publication number: WO 2024/191428 (19.09.2024 Gazette 2024/38)

(84) Designated Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR Designated Extension States: BA Designated Validation States: KH MA MD TN (30) Priority: 14.03.2023 US 202363452127 P (71) Applicant: Sigilon Therapeutics, Inc. Cambridge, MA 02142 (US)

(72) Inventors: BUCHANAN, Matthew Cambridge, MA 02142 (US) SPARAGES, Christopher, A. Cambridge, MA 02142 (US) DE PAOLIS, Omar Cambridge, MA 02142 (US) MCCLATCHEY, P. Mason Cambridge, MA 02142 (US) HARRINGTON, Roger, E. Cambridge, MA 02142 (US) JANSEN, Lauren, E. Cambridge, MA 02142 (US) (74) Representative: Snaith, James Michael et al Kilburn & Strode LLP Lacon London 84 Theobalds Road London WC1X 8NL London WC1X 8NL (GB)